Alexion Pharmaceuticals, Inc. (ALXN) Shares Bought by Canada Pension Plan Investment Board

Cornelia Mascio
Novembre 14, 2017

The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. The company had a trading volume of 1,620,000 shares, compared to its average volume of 2,289,474.

Other large investors also recently bought and sold shares of the company. Huntington National Bank increased its stake in shares of Alexion Pharmaceuticals by 1,084.6% in the second quarter. BlackRock Inc. now owns 19,926,265 shares of the biopharmaceutical company's stock worth $2,424,428,000 after buying an additional 1,298,185 shares in the last quarter. Numeric Ltd Liability stated it has 0.01% of its portfolio in Alexion Pharmaceuticals, Inc. The fund owned 41,167 shares of the biopharmaceutical company's stock after selling 1,950 shares during the quarter. State Street Corp grew its position in shares of Alexion Pharmaceuticals by 5.0% during the 2nd quarter. Finally, Grove Bank & Trust increased its stake in shares of Alexion Pharmaceuticals by 194.7% in the second quarter. Vanguard Group Inc. now owns 14,785,831 shares of the biopharmaceutical company's stock worth $1,798,992,000 after buying an additional 318,375 shares in the last quarter. Institutional investors and hedge funds own 96.71% of the company's stock. The Japan-based Nippon Life Insurance Co has invested 0.02% in Alexion Pharmaceuticals, Inc. (ALXN) opened at $113.45 on Tuesday. The company has a debt-to-equity ratio of 0.35, a current ratio of 2.96 and a quick ratio of 2.51. The stock has a market capitalization of $28.59 billion, a PE ratio of 77.76 and a beta of 1.45.

Brief Synopsis On Alexion Pharmaceuticals Inc. (NASDAQ:ALXN) news were published by: which released: "Alexion Pharmaceuticals (ALXN) Q3 2017 Results - Earnings Call Transcript" on October 26, 2017. The biopharmaceutical company reported $1.23 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.04 by $0.19. The company earned $799 million during the quarter, compared to analyst estimates of $787.07 million. Alexion Pharmaceuticals had a net margin of 12.46% and a return on equity of 10.58%. The business's revenue for the quarter was up 7.5% compared to the same quarter last year. analysts forecast that Alexion Pharmaceuticals, Inc. will post 4.81 EPS for the current year. During the same period in the previous year, the firm earned $1.23 EPS. Takes $2.80 Million Position in Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) for 163,641 shares.

TRADEMARK VIOLATION NOTICE: This piece was reported by StockNewsTimes and is the property of of StockNewsTimes. Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) has declined 18.12% since November 13, 2016 and is downtrending.

In other news, Director Ann M. Veneman sold 835 shares of the stock in a transaction dated Tuesday, September 5th. The shares were sold at an average price of $137.14, for a total value of $45,530.48. Following the completion of the transaction, the director now directly owns 6,373 shares in the company, valued at approximately $870,105.69. The stock was sold at an average price of $136.53, for a total transaction of $2,047,950.00. Following the sale, the executive vice president now directly owns 26,704 shares of the company's stock, valued at approximately $3,738,560. The disclosure for this sale can be found here. The Artal Group Sa holds 20,900 shares with $2.54 million value, down from 100,000 last quarter. Corporate insiders own 4.35% of the company's stock.

ALXN has been the subject of a number of analyst reports. Morgan Stanley reiterated an "overweight" rating and issued a $153.00 price target (up previously from $141.00) on shares of Alexion Pharmaceuticals in a report on Friday, July 28th. Six equities research analysts have rated the stock with a hold rating, eighteen have given a buy rating and two have given a strong buy rating to the company's stock. Royal Bank Of Canada began coverage on shares of Alexion Pharmaceuticals in a research report on Thursday, September 14th. Stifel Nicolaus decreased their price objective on Alexion Pharmaceuticals from $165.00 to $159.00 and set a "buy" rating for the company in a research note on Tuesday, October 24th. Finally, Piper Jaffray Companies restated an "overweight" rating and set a $170.00 target price on shares of Alexion Pharmaceuticals in a research note on Monday, October 23rd. The company presently has an average rating of "Buy" and an average target price of $154.01. Meeder Asset Management Inc. acquired a new position in shares of Alexion Pharmaceuticals during the first quarter valued at about $114,000. The Company's product line includes new and remanufactured automotive hard parts, such as alternators, starters, fuel pumps, water pumps, brake system components, batteries, belts, hoses, temperature control, chassis parts, driveline parts and engine parts; maintenance items, such as oil, antifreeze, fluids, filters, wiper blades, lighting, engine additives and appearance products, and accessories, such as floor mats, seat covers and truck accessories.

Altre relazioniGrafFiotech

Discuti questo articolo

Segui i nostri GIORNALE